Intravitreous Avastin for diseases of ocular angiogensis

Phase 1

Recruiting

• Conditions: Age Related Macular Degeneration; Neovascular Glaucoma; Proliferative Diabetic retinopathy; Eye - Diseases / disorders of the eye; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12607000244404
• Lead Sponsor: Royal Victorian Eye and Ear Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-05-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Neovascular Age related macular degeneration.2. Neovascular glaucoma3. Proliferative diabetic retinopathy4. subjects able to give informed consent.

Exclusion Criteria

1. History of unstable cardiovascular disease (CVA, TIA or AMI)2. Previous treatment with Lucentis3. Intravenous treatment with Avastin for systemic malignancy4. Inability to read and fully understand detailed consent form5. first eyes in patients with AMD6. allergy to AvastinCVA- strokeAMI-heart attackTIA- mini-stroke.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Snellen visual acuity (measured in all patients)[At 3 monthly intervals and as well as baseline, until the end of the study at 12 months.];2.the presence or absence of Intra-retinal and sub-retinal fluid (in patients with Age related macular degeneration only).[Assesed by Optical coherence tomography. Measured at 3 monthly intervals and at baseline, until completion of the study at 12 months.];3. The presence or absence of ocular neovascularization (in patients with neovascular glaucoma and diabetic retinopathy). Assessed by Slit lamp examination.[Measured at baseline and at 4 weekly intervals until the completion of the study in 12 months.];4. Intraocular pressure (in patients with neovascular glaucoma). This will be measured by Goldman tonometry.[Measured at baseline (at enrolment) and 3 monthly following treatment until 12 months at the completion of the study.]

Secondary Outcome Measures

Name	Time	Method
Incidence of severe visual loss (visual acuity <6/60).[This will be measured at baseline, then 3 monthly until 12 months.]